Francis Mah, MD
Ophthalmology · Pittsburgh, PANPI 1528032620
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (48.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 14.5%. Among ophthalmology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,444 payments — averaging $773.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$162K
- Oyster Point Pharma, Inc.$143K
- AbbVie$96K
- Kala Pharmaceuticals, Inc.$94K
- Johnson & Johnson Surgical Vision, Inc.$89K
- ANI Pharmaceuticals, Inc.$79K
- plus $453K from 31 others
Across 14 payments — averaging $3995.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sight Sciences, Inc.$49K
- Ocular Therapeutix, Inc.$6K
- AbbVie$583
What the payments were for
- Consulting fees$435,10839%
- Speaking & faculty fees$544,51749%
- Travel & lodging$74,9237%
- Food & beverage$43,6924%
- Education$18,8102%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIIDRA$139,715
- TYRVAYA$139,182
- PURIFIED CORTROPHIN GEL$77,867
- CEQUA$63,466
- Oxervate$58,946
- MIEBO$55,604
- INVELTYS$45,488
- EYSUVIS$42,525
- ACTHAR$40,180
- Catalys Laser System$37,067
- COMPACT INTUITIV Phacofragmentation System$37,067
- Healon Viscoelastics$37,067
- enVista MX60 IOL$30,639
- BLENREP$28,439
- Crystalens Accommodating IOL (AT-52AO)$27,873
- Tecnis IOL$27,000
- STELLARIS ELITE$24,473
- Trulign IOL$24,473
- Compact Intuitiv$23,407
- Healon Duet Pro$23,407
How this compares
$1,117,051 in reported general payments places this provider in the 95th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 40 | $56,520 |
| RestasisCyclosporine | 25 | $33,706 |
| MieboPerfluorohexyloctane/Pf | 42 | $32,941 |
| ProlensaBromfenac Sodium | 80 | $28,774 |
| Cyclosporine | 39 | $25,832 |
| FlarexFluorometholone Acetate | 124 | $16,252 |
| InveltysLoteprednol Etabonate | 26 | $7,683 |
| LumiganBimatoprost | 12 | $5,521 |
| Loteprednol Etabonate | 25 | $4,913 |
| Bromfenac Sodium | 26 | $4,464 |
| Prednisolone Acetate | 59 | $1,895 |
| Acyclovir | 47 | $1,351 |
| Fluorometholone | 17 | $1,198 |
| MoxifloxacinMoxifloxacin Hcl | 26 | $662 |
| Latanoprost | 29 | $540 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $162,407 | $89,46182 claims |
| AbbVieRestasis, Lumigan | $96,182 | $39,22737 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $8,743 | $33,687105 claims |
| Eyevance Pharmaceuticals LLCFlarex | $7,887 | $16,252124 claims |
| Kala Pharmaceuticals, Inc.Inveltys | $93,993 | $7,68326 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 920 ophthalmology providers in Pennsylvania.
Other ophthalmology in Pittsburgh
- Robert NoeckerPittsburgh$632K
- Srinivas KondapalliPittsburgh$208K
- Deval ParanjpePittsburgh$121K
- Ian ConnerPittsburgh$82K
- Deepinder DhaliwalPittsburgh$65K
- Thomas FribergPittsburgh$55K
- Jenny YuPittsburgh$47K
- Vishal JhanjiPittsburgh$38K
- Omar AbbasiPittsburgh$36K
- Julia HallerPhiladelphia$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.